Log In
BCIQ
Print this Print this
 

Biosimilar abatacept (M834)

  Manage Alerts
Collapse Summary General Information
Company Momenta Pharmaceuticals Inc.
DescriptionBiosimilar of Orencia abatacept, a CTLA-4 (CD152)-Ig fusion protein
Molecular Target
Mechanism of ActionBiosimilar
Therapeutic ModalityBiologic: Fusion protein

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$697.0M

$78.0M

$591.0M


 Deals Details
Get a free BioCentury trial today